Hepatic targeting of the centrally active cannabinoid 1 receptor (CB

Mice Animals Rimonabant / therapeutic use Cannabinoid Receptor Antagonists / therapeutic use Non-alcoholic Fatty Liver Disease / drug therapy Diabetes Mellitus, Type 2 / drug therapy Obesity / drug therapy Cannabinoids / therapeutic use
CB1 receptor blocker Drug delivery system Hepatic steatosis Insulin resistance Nanomedicine Obesity Polymeric nanoparticles

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
01 2023
Historique:
received: 12 07 2022
revised: 10 11 2022
accepted: 22 11 2022
pubmed: 29 11 2022
medline: 3 2 2023
entrez: 28 11 2022
Statut: ppublish

Résumé

Over-activation of the endocannabinoid/CB

Identifiants

DOI: 10.1016/j.jconrel.2022.11.040 PMID: 36442615 PMC: PMC9900386
pubmed: 36442615
pii: S0168-3659(22)00786-6
doi: 10.1016/j.jconrel.2022.11.040
pmc: PMC9900386
mid: EMS186828
pii:
doi:

Substances chimiques

Rimonabant RML78EN3XE
Cannabinoid Receptor Antagonists 0
Cannabinoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-269

Subventions

Organisme : European Research Council
ID : 101100628
Pays : International

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Références

J Hepatol. 2013 Oct;59(4):891-6
pubmed: 23567085
Annu Rev Pharmacol Toxicol. 2012;52:481-503
pubmed: 22035254
Lancet. 2006 Nov 11;368(9548):1660-72
pubmed: 17098084
Nat Rev Endocrinol. 2011 May 10;7(8):456-65
pubmed: 21556019
Diabetes Care. 2008 Nov;31(11):2169-76
pubmed: 18678611
Mol Metab. 2020 Dec;42:101087
pubmed: 32987186
Eur J Pharmacol. 2009 Aug 15;616(1-3):314-20
pubmed: 19482020
Nano Lett. 2015 Apr 8;15(4):2358-64
pubmed: 25811353
Mol Pharmacol. 2011 Nov;80(5):859-69
pubmed: 21803969
Gastroenterology. 2012 May;142(5):1218-1228.e1
pubmed: 22307032
Behav Brain Res. 2007 Jan 25;176(2):210-5
pubmed: 17098297
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
J Clin Invest. 2010 Aug;120(8):2953-66
pubmed: 20664173
FASEB J. 2007 Sep;21(11):2798-806
pubmed: 17440119
Br J Pharmacol. 2005 Jun;145(3):293-300
pubmed: 15778743
Life Sci. 1998;63(8):PL113-7
pubmed: 9718088
Eur J Pharmacol. 2001 Mar 2;414(2-3):135-43
pubmed: 11239913
Mol Metab. 2016 Oct 22;5(12):1187-1199
pubmed: 27900261
Front Biosci (Landmark Ed). 2016 Jun 01;21(7):1488-501
pubmed: 27100518
Hepatology. 2011 Jan;53(1):346-55
pubmed: 21254182
Hepatology. 2007 Jul;46(1):122-9
pubmed: 17526015
Gut. 2005 Apr;54(4):522-7
pubmed: 15753538
STAR Protoc. 2020 Aug 13;1(2):100086
pubmed: 33111119
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1162-70
pubmed: 19724020
Behav Brain Res. 2011 Mar 1;217(2):432-8
pubmed: 21074566
Br J Pharmacol. 2006 Dec;149(7):898-908
pubmed: 17043671
Can J Physiol Pharmacol. 2017 Dec;95(12):1433-1441
pubmed: 28759733
J Am Soc Nephrol. 2017 Dec;28(12):3518-3532
pubmed: 28860163
Psychopharmacology (Berl). 1997 Jul;132(1):104-6
pubmed: 9272766
Mol Psychiatry. 2013 Dec;18(12):1294-301
pubmed: 23070073
J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80
pubmed: 16684820
Eur J Endocrinol. 2009 Nov;161(5):715-22
pubmed: 19745037
Hepatology. 2012 Mar;55(3):790-9
pubmed: 21987372
Obes Surg. 2019 Jan;29(1):268-276
pubmed: 30244333
Cell Metab. 2012 Aug 8;16(2):167-79
pubmed: 22841573
Cells. 2021 Feb 17;10(2):
pubmed: 33671138
Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32
pubmed: 17296341
J Clin Invest. 2008 Sep;118(9):3160-9
pubmed: 18677409
Lancet. 2007 Nov 17;370(9600):1706-13
pubmed: 18022033
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Int J Clin Pract. 2011 Jun;65(6):713-5
pubmed: 21564446
Psychopharmacology (Berl). 2013 Aug;228(3):401-9
pubmed: 23483200
Oxid Med Cell Longev. 2015;2015:842108
pubmed: 26078820
Hepatology. 2014 Jan;59(1):143-53
pubmed: 23832510
Diabetes Care. 2010 Mar;33(3):605-7
pubmed: 20009090
Biochemistry (Mosc). 2019 Aug;84(8):954-962
pubmed: 31522677
Obesity (Silver Spring). 2011 Oct;19(10):1923-34
pubmed: 21799481
J Neuroendocrinol. 2008 May;20 Suppl 1:147-51
pubmed: 18426514
Handb Exp Pharmacol. 2005;(168):53-79
pubmed: 16596771
Diabetologia. 2018 Jun;61(6):1470-1483
pubmed: 29497784
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
Dis Model Mech. 2016 Jan;9(1):51-61
pubmed: 26563389
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:22-31
pubmed: 25496830
Curr Top Med Chem. 2019;19(16):1418-1435
pubmed: 31284863
Diabetes Obes Metab. 2019 Jan;21(1):146-159
pubmed: 30091204
Diabetes. 2010 Apr;59(4):926-34
pubmed: 20110567
Metabolism. 2010 May;59(5):734-41
pubmed: 19919870
J Clin Invest. 2021 Nov 15;131(22):
pubmed: 34499619
Eur J Intern Med. 2018 Mar;49:23-29
pubmed: 29336868
Pharmacol Rev. 2001 Jun;53(2):283-318
pubmed: 11356986
Mater Sci Eng C Mater Biol Appl. 2015 Mar;48:328-36
pubmed: 25579930
Pharmacol Biochem Behav. 2000 Oct;67(2):265-70
pubmed: 11124390
J Hepatol. 2008;48 Suppl 1:S104-12
pubmed: 18304679
Hepatology. 2019 Apr;69(4):1535-1548
pubmed: 30506571
Pharmacol Ther. 2020 Apr;208:107477
pubmed: 31926199
J Clin Invest. 2017 Nov 1;127(11):4148-4162
pubmed: 29035280
Diabetes. 2006 Nov;55(11):3053-60
pubmed: 17065342
Diabetologia. 2009 Apr;52(4):664-74
pubmed: 19089403
J Control Release. 2016 Oct 28;240:332-348
pubmed: 26774224
Toxins (Basel). 2019 May 15;11(5):
pubmed: 31096702
Eur J Clin Invest. 2004 Apr;34(4):283-9
pubmed: 15086360
N Engl J Med. 2005 Nov 17;353(20):2121-34
pubmed: 16291982
J Clin Invest. 2003 Aug;112(3):423-31
pubmed: 12897210
Chem Phys Lipids. 2017 Apr;204:85-93
pubmed: 28363784
JAMA. 2006 Feb 15;295(7):761-75
pubmed: 16478899
Obesity (Silver Spring). 2017 Jan;25(1):94-101
pubmed: 27863097
J Gastroenterol Hepatol. 2004 Aug;19(8):854-8
pubmed: 15242486
Obesity (Silver Spring). 2009 Aug;17(8):1641-5
pubmed: 19325539
Behav Pharmacol. 2005 Sep;16(5-6):381-8
pubmed: 16148442
Obesity (Silver Spring). 2014 Jan;22(1):211-6
pubmed: 23616305
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
pubmed: 12399252
Rev Gastroenterol Mex. 2005 Nov;70 Suppl 3:52-6
pubmed: 17471859
Nat Med. 2006 Jun;12(6):671-6
pubmed: 16715087
Nature. 2001 Apr 12;410(6830):822-5
pubmed: 11298451
Nat Rev Drug Discov. 2008 Dec;7(12):961-2
pubmed: 19043439
FASEB J. 2005 Sep;19(11):1567-9
pubmed: 16009704
Mol Pharm. 2008 Jul-Aug;5(4):496-504
pubmed: 18611037
Lancet. 2007 Feb 17;369(9561):555
pubmed: 17307094
Elife. 2020 Nov 19;9:
pubmed: 33210603
Behav Pharmacol. 1998 Mar;9(2):179-81
pubmed: 10065938
Lipids Health Dis. 2014 Nov 18;13:173
pubmed: 25406988
Mol Metab. 2017 Nov;6(11):1517-1528
pubmed: 29107297
Diabetes. 2005 Oct;54(10):2838-43
pubmed: 16186383
J Cell Mol Med. 2021 Oct;25(20):9878-9883
pubmed: 34558178
Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68
pubmed: 24381003
J Control Release. 1999 May 1;59(1):15-22
pubmed: 10210718
Int J Mol Sci. 2019 May 22;20(10):
pubmed: 31121839
J Clin Pharm Ther. 2007 Jun;32(3):209-31
pubmed: 17489873
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23
pubmed: 19112166
Lancet. 2005 Apr 16-22;365(9468):1389-97
pubmed: 15836887
FASEB J. 2019 May;33(5):5850-5863
pubmed: 30726112
Nat Med. 2001 Jul;7(7):827-32
pubmed: 11433348
J Am Soc Nephrol. 2018 Feb;29(2):434-448
pubmed: 29030466
Int J Obes (Lond). 2007 Apr;31(4):692-9
pubmed: 17224929

Auteurs

Shira Hirsch (S)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel.

Liad Hinden (L)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel.

Meital Ben-David Naim (MB)

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Saja Baraghithy (S)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel.

Anna Permyakova (A)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel.

Shahar Azar (S)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel.

Taher Nasser (T)

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Emma Portnoy (E)

Department of Biochemistry, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Israel.

Majd Agbaria (M)

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Alina Nemirovski (A)

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Gershon Golomb (G)

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Joseph Tam (J)

Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel; The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel. Electronic address: yossi.tam@mail.huji.ac.il.

Articles similaires

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Hepatic targeting of the centrally active...
questionsmedicales.fr › Eucaryotes › Animaux › Hepatic targeting of the centrally active...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Rimonabant › Hepatic targeting of the centrally active...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Modulateurs des récepteurs de cannabinoïdes › Antagonistes des récepteurs de cannabinoïdes › Hepatic targeting of the centrally active...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Stéatose hépatique › Stéatose hépatique non alcoolique › Hepatic targeting of the centrally active...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Hepatic targeting of the centrally active...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Hepatic targeting of the centrally active...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Hepatic targeting of the centrally active...